Strain-Dependent Effects of Dietary Cholic Acid on Liver Fibrogenesis and Gut Microbiota in TSNO and TSOD Mice
Abstract
1. Introduction
2. Materials and Methods
2.1. Animal Studies
2.2. Plasma Chemistry
2.3. Non-Parenchymal Cell Isolation
2.4. Flow Cytometry
2.5. Quantitative Real-Time PCR
2.6. Liver Histology and Immunohistochemistry
2.7. Metagenomic 16S rRNA Sequencing
2.8. Bacterial Community Analysis
2.9. qPCR Analysis for Relative Abundance of A. muciniphila
2.10. Bile Acid Analysis
2.11. Statistical Analysis
3. Results
3.1. Dietary CA Induces Hepatomegaly, Liver Injury, and Lipid Metabolism Abnormalities in TSOD and TSNO Mice
3.2. Dietary CA Promotes Fibrotic Change in the Liver of TSNO Mice
3.3. Dietary CA Upregulates the Expression Levels of Macrophage- and Fibrosis-Related Genes in the Liver of TSNO Mice
3.4. Dietary CA Promotes Leukocyte Infiltration in the Livers of TSNO and TSOD Mice
3.5. Dietary CA Reduces KC Count and Promotes MdM Accumulation in the Liver
3.6. CA Supplementation to ND Induces CD11c+/Ly6C− and CD11c−/Ly6C+ MdM Subset Accumulation
3.7. CA Is Essential for the iHFC-Induced Increase in Intestinal Abundance of A. muciniphila
3.8. Fecal BA Profiles Reveal Differential Responses to CA Supplementation in TSOD and TSNO Mice
4. Discussion
4.1. Hepatic Effects of Dietary CA
4.2. Alterations in Hepatic Macrophage Populations
4.3. Effects of CA on Gut Microbiota and BA Metabolism
4.4. Integration of Hepatic and Intestinal Responses
4.5. Limitations and Perspectives
4.6. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| 7-AAD | 7-amino-actinomycin D |
| ALP | alkaline phosphatase |
| ALT | alanine aminotransferase |
| BA | bile acid |
| CA | cholic acid |
| DCA | deoxycholic acid |
| FXR | farnesoid X receptor |
| GGT | γ-glutamyltransferase |
| hCLS | hepatic crown-like structure |
| H&E | hematoxylin and eosin |
| KC | Kupffer cell |
| LCA | lithocholic acid |
| MASH | metabolic dysfunction-associated steatohepatitis |
| MCA | muricholic acid |
| MdM | monocyte-derived macrophage |
| NAS | NAFLD activity score |
| ND | normal diet |
| PCA | principal component analysis |
| T2DM | type 2 diabetes mellitus |
| T-Bil | total bilirubin |
| TCA | taurocholic acid |
| T-CHO | total cholesterol |
| TDCA | taurodeoxycholic acid |
| TG | triglyceride |
| TMCA | tauromuricholic acid |
| TSNO | Tsumura–Suzuki non-obese |
| TSOD | Tsumura–Suzuki obese diabetes |
References
- Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016, 64, 73–84. [Google Scholar] [CrossRef]
- Estes, C.; Razavi, H.; Loomba, R.; Younossi, Z.; Sanyal, A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018, 67, 123–133. [Google Scholar] [CrossRef]
- Anstee, Q.M.; Targher, G.; Day, C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 330–344. [Google Scholar] [CrossRef]
- Rinella, M.E. Nonalcoholic fatty liver disease: A systematic review. JAMA 2015, 313, 2263–2273. [Google Scholar] [CrossRef]
- Tacke, F. Targeting hepatic macrophages to treat liver diseases. J. Hepatol. 2017, 66, 1300–1312. [Google Scholar] [CrossRef] [PubMed]
- Krenkel, O.; Tacke, F. Liver macrophages in tissue homeostasis and disease. Nat. Rev. Immunol. 2017, 17, 306–321. [Google Scholar] [CrossRef]
- Itoh, M.; Kato, H.; Suganami, T.; Konuma, K.; Marumoto, Y.; Terai, S.; Sakugawa, H.; Kanai, S.; Hamaguchi, M.; Fukaishi, T.; et al. Hepatic crown-like structure: A unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS ONE 2013, 8, e82163. [Google Scholar] [CrossRef] [PubMed]
- Lefere, S.; Van de Velde, F.; Devisscher, L.; Bekaert, M.; Raevens, S.; Verhelst, X.; Van Nieuwenhove, Y.; Praet, M.; Hoorens, A.; Van Steenkiste, C.; et al. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. Int. J. Obes. 2017, 41, 1207–1213. [Google Scholar] [CrossRef]
- Ramachandran, P.; Pellicoro, A.; Vernon, M.A.; Boulter, L.; Aucott, R.L.; Ali, A.; Hartland, S.N.; Snowdon, V.K.; Cappon, A.; Gordon-Walker, T.T.; et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc. Natl. Acad. Sci. USA 2012, 109, E3186–E3195. [Google Scholar] [CrossRef]
- Chiang, J.Y.L.; Ferrell, J.M. Bile Acids as Metabolic Regulators and Nutrient Sensors. Annu. Rev. Nutr. 2019, 39, 175–200. [Google Scholar] [CrossRef] [PubMed]
- Pols, T.W.; Nomura, M.; Harach, T.; Lo Sasso, G.; Oosterveer, M.H.; Thomas, C.; Rizzo, G.; Gioiello, A.; Adorini, L.; Pellicciari, R.; et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011, 14, 747–757. [Google Scholar] [CrossRef]
- Kong, B.; Luyendyk, J.P.; Tawfik, O.; Guo, G.L. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J. Pharmacol. Exp. Ther. 2009, 328, 116–122. [Google Scholar] [CrossRef]
- Wahlstrom, A.; Sayin, S.I.; Marschall, H.U.; Backhed, F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab. 2016, 24, 41–50. [Google Scholar] [CrossRef] [PubMed]
- Ridlon, J.M.; Kang, D.J.; Hylemon, P.B.; Bajaj, J.S. Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 2014, 30, 332–338. [Google Scholar] [CrossRef]
- Everard, A.; Belzer, C.; Geurts, L.; Ouwerkerk, J.P.; Druart, C.; Bindels, L.B.; Guiot, Y.; Derrien, M.; Muccioli, G.G.; Delzenne, N.M.; et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. USA 2013, 110, 9066–9071. [Google Scholar] [CrossRef]
- Depommier, C.; Everard, A.; Druart, C.; Plovier, H.; Van Hul, M.; Vieira-Silva, S.; Falony, G.; Raes, J.; Maiter, D.; Delzenne, N.M.; et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study. Nat. Med. 2019, 25, 1096–1103. [Google Scholar] [CrossRef]
- Friedman, S.L.; Neuschwander-Tetri, B.A.; Rinella, M.; Sanyal, A.J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 2018, 24, 908–922. [Google Scholar] [CrossRef] [PubMed]
- Ichimura-Shimizu, M.; Omagari, K.; Yamashita, M.; Tsuneyama, K. Development of a novel mouse model of diet-induced nonalcoholic steatohepatitis-related progressive bridging fibrosis. Biosci. Biotechnol. Biochem. 2021, 85, 941–947. [Google Scholar] [CrossRef]
- Tada, Y.; Kasai, K.; Makiuchi, N.; Igarashi, N.; Kani, K.; Takano, S.; Honda, H.; Yanagibashi, T.; Watanabe, Y.; Usui-Kawanishi, F.; et al. Roles of Macrophages in Advanced Liver Fibrosis, Identified Using a Newly Established Mouse Model of Diet-Induced Non-Alcoholic Steatohepatitis. Int. J. Mol. Sci. 2022, 23, 13251. [Google Scholar] [CrossRef] [PubMed]
- Igarashi, N.; Kasai, K.; Tada, Y.; Kani, K.; Kato, M.; Takano, S.; Goto, K.; Matsuura, Y.; Ichimura-Shimizu, M.; Watanabe, S.; et al. Impacts of liver macrophages, gut microbiota, and bile acid metabolism on the differences in iHFC diet-induced MASH progression between TSNO and TSOD mice. Inflamm. Res. 2024, 73, 1081–1098. [Google Scholar] [CrossRef]
- Goto, K.; Kani, K.; Kato, M.; Igarashi, N.; Tada, Y.; Kasai, K.; Ichimura-Shimizu, M.; Watanabe, S.; Tsuneyama, K.; Furusawa, Y.; et al. Critical Role of Cholic Acid in the Development of iHFC Diet-induced MASH in TSNO Mice. Inflammation 2025, 48, 3726–3744. [Google Scholar] [CrossRef] [PubMed]
- Kato, M.; Goto, K.; Kani, K.; Igarashi, N.; Kasai, K.; Tada, Y.; Yoshimoto, Y.; Watanabe, Y.; Honda, H.; Ichimura-Shimizu, M.; et al. Cholic Acid-Induced Akkermansia Expansion and FGF-15 Upregulation Improve Diabetes While Exacerbating Steatohepatitis in TSOD Mice. Genes Cells 2025, 30, e70069. [Google Scholar] [CrossRef]
- Kleiner, D.E.; Brunt, E.M.; Van Natta, M.; Behling, C.; Contos, M.J.; Cummings, O.W.; Ferrell, L.D.; Liu, Y.C.; Torbenson, M.S.; Unalp-Arida, A.; et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41, 1313–1321. [Google Scholar] [CrossRef] [PubMed]
- Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9, 671–675. [Google Scholar] [CrossRef]
- Chavez-Talavera, O.; Tailleux, A.; Lefebvre, P.; Staels, B. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology 2017, 152, 1679–1694.e3. [Google Scholar] [CrossRef]
- Reid, D.T.; Reyes, J.L.; McDonald, B.A.; Vo, T.; Reimer, R.A.; Eksteen, B. Kupffer Cells Undergo Fundamental Changes during the Development of Experimental NASH and Are Critical in Initiating Liver Damage and Inflammation. PLoS ONE 2016, 11, e0159524. [Google Scholar] [CrossRef]
- Caussy, C.; Tripathi, A.; Humphrey, G.; Bassirian, S.; Singh, S.; Faulkner, C.; Bettencourt, R.; Rizo, E.; Richards, L.; Xu, Z.Z.; et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat. Commun. 2019, 10, 1406. [Google Scholar] [CrossRef]
- Kazankov, K.; Jorgensen, S.M.D.; Thomsen, K.L.; Moller, H.J.; Vilstrup, H.; George, J.; Schuppan, D.; Gronbaek, H. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 145–159. [Google Scholar] [CrossRef] [PubMed]








Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Aoyama, T.; Iwata, N.; Kawamoto, S.; Kato, M.; Kani, K.; Kasai, K.; Goto, K.; Yoshimoto, Y.; Ichimura-Shimizu, M.; Watanabe, S.; et al. Strain-Dependent Effects of Dietary Cholic Acid on Liver Fibrogenesis and Gut Microbiota in TSNO and TSOD Mice. Biomedicines 2026, 14, 442. https://doi.org/10.3390/biomedicines14020442
Aoyama T, Iwata N, Kawamoto S, Kato M, Kani K, Kasai K, Goto K, Yoshimoto Y, Ichimura-Shimizu M, Watanabe S, et al. Strain-Dependent Effects of Dietary Cholic Acid on Liver Fibrogenesis and Gut Microbiota in TSNO and TSOD Mice. Biomedicines. 2026; 14(2):442. https://doi.org/10.3390/biomedicines14020442
Chicago/Turabian StyleAoyama, Taeko, Nanako Iwata, Saki Kawamoto, Miyuna Kato, Koudai Kani, Kaichi Kasai, Kana Goto, Yousei Yoshimoto, Mayuko Ichimura-Shimizu, Shiro Watanabe, and et al. 2026. "Strain-Dependent Effects of Dietary Cholic Acid on Liver Fibrogenesis and Gut Microbiota in TSNO and TSOD Mice" Biomedicines 14, no. 2: 442. https://doi.org/10.3390/biomedicines14020442
APA StyleAoyama, T., Iwata, N., Kawamoto, S., Kato, M., Kani, K., Kasai, K., Goto, K., Yoshimoto, Y., Ichimura-Shimizu, M., Watanabe, S., Tsuneyama, K., Furusawa, Y., & Nagai, Y. (2026). Strain-Dependent Effects of Dietary Cholic Acid on Liver Fibrogenesis and Gut Microbiota in TSNO and TSOD Mice. Biomedicines, 14(2), 442. https://doi.org/10.3390/biomedicines14020442

